Retatrutide Creates a 1,200-Calorie Deficit. Tirzepatide Creates 750. For Most Australian Lifters, the Bigger Number Is the Wrong Choice.

ProtocolHub provides educational information only. All GLP-1 therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

Practitioners estimate that Retatrutide drives a caloric deficit of roughly 1,100–1,300 calories per day above your baseline — achieved through both appetite suppression and glucagon-driven thermogenesis. Tirzepatide is estimated at roughly 700–800 calories per day, primarily through appetite suppression. These are practitioner-extrapolated figures, not directly measured values from published trials, but the directional gap is supported by the mechanistic differences between the two drugs and by the weight-loss outcomes observed in Phase 2 and Phase 3 data. Retatrutide is categorically more powerful. For most Australian lifters — anyone who has invested serious time building muscle and wants to preserve it — that extra 400–500 calorie gap is the reason to choose Tirzepatide. Here is the mechanism behind why, the evidence, the RHR risk most people aren't talking about, and a precise decision framework for choosing the right tool for your goal.

Retatrutide vs Tirzepatide — the numbers that matter

	Tirzepatide	Retatrutide
Mechanism	Dual GIP + GLP-1 agonist	Triple GIP + GLP-1 + glucagon agonist
Estimated daily deficit	~700–800 kcal (practitioner estimate)	~1,100–1,300 kcal (practitioner estimate)
How deficit is created	Primarily appetite suppression	Appetite suppression + thermogenesis
Protein sparing design	Moderate — GIP component helps	No — thermogenesis-driven, not designed for it
Average weight loss (trials)	20.9% bodyweight over 72 weeks	~24% bodyweight over 48 weeks (Phase 2)
Resting heart rate increase	Modest	Meaningfully larger — glucagon activates thermogenesis
For lifters	Better choice	Worse choice unless maximum speed is the goal
TGA status (Australia)	Approved for T2 diabetes; off-label for weight loss	Phase 3 trials — not yet approved or accessible
Australian access	Off-label compounded prescription	Not currently available

Why Retatrutide isn't the upgrade it looks like — the thermogenesis problem

The extra 400–500 calories of deficit Retatrutide creates doesn't come from eating less. It comes from burning more.

Retatrutide's third receptor target — glucagon — activates brown adipose tissue thermogenesis. Your body generates more heat, burns more energy at rest, and the caloric expenditure increases directly. This is why it produces a larger deficit than Tirzepatide at equivalent appetite suppression levels.

The problem for anyone carrying muscle they want to keep: Retatrutide was not designed to be protein-sparing. Tirzepatide's dual GIP/GLP-1 mechanism has a modest lean mass preservation advantage — the GIP receptor has direct activity on adipose tissue that preferentially targets fat. Retatrutide's thermogenic mechanism does not discriminate. It burns more energy, and it is agnostic about where that energy comes from.

When a deficit of 1,200 calories per day is met without adequate protein intake and resistance training, a meaningfully higher proportion of that deficit comes from lean mass catabolism than in a 750-calorie deficit on Tirzepatide. The deeper the hole, the harder it is to fill it with fat alone.

For someone with 30 kg of body fat to lose, this trade-off is manageable. For someone with 10 kg to lose who has spent five years building 20 kg of muscle, the calculus is completely different.

The RHR problem nobody is talking about

Thermogenesis doesn't just increase caloric expenditure. It increases resting heart rate.

Glucagon receptor agonism — the component unique to Retatrutide — activates the sympathetic nervous system as part of the thermogenic cascade. The practical expectation, based on glucagon's known sympathomimetic effects, is a greater increase in resting heart rate than Tirzepatide. The NEJM Phase 2 paper notes the overall side-effect profile was "similar to GLP-1 and GIP–GLP-1 receptor agonists," but the cardiovascular load from sustained thermogenic activation is a real clinical consideration that warrants monitoring.

The clinical significance of this varies by individual. For a healthy 35-year-old with normal cardiac baseline, an elevated RHR is uncomfortable and worth monitoring but not immediately dangerous. For anyone with existing cardiovascular risk factors, hypertension, or arrhythmia history, this signal warrants a more conservative approach and explicit discussion with an AHPRA-registered prescriber before starting.

For serious lifters: elevated resting heart rate also impairs recovery. Heart rate variability (HRV) — the metric most serious athletes use to gauge recovery quality — will suffer at chronically elevated RHR. If your training volume is high and recovery is already a limiting factor, Retatrutide's cardiovascular load is another argument for Tirzepatide.

The plateau is inevitable — this is why, and it changes the drug choice

Here is the most important concept neither compound's marketing will tell you: every GLP-1 agent plateaus. Every single one.

The mechanism is not the drug stopping to work. It is basic biology. As you lose body fat, two things happen simultaneously:

1. Your body gets lighter — so it burns fewer calories at rest. A 110 kg body at 25% body fat burns more calories daily than a 90 kg body at 18% body fat. The deficit that drove weight loss at the start of treatment narrows naturally as your body mass decreases.

2. Appetite up-regulates as body fat decreases. This is the part most people find unfair. Leptin — the hormone that signals satiety — is produced by fat cells. The leaner you become, the less leptin you produce, and the harder your brain fights to drive you back toward eating. The drug partially suppresses this signal. But as fat drops, the up-regulation grows stronger and increasingly counteracts the drug's appetite suppression.

This is why it is biologically harder to be very lean. It is not willpower failure. It is your body fighting for homeostasis. The GLP-1 drug is holding back a door that gets heavier as you lose more fat.

How this affects the drug choice: Retatrutide's larger deficit means it reaches the plateau faster in absolute terms — significant weight loss happens more quickly, but the physiological resistance intensifies sooner. Tirzepatide's more moderate deficit extends the productive weight loss window over a longer period, which is more compatible with a resistance training programme that needs consistent fuelling and recovery.

Find an Australian prescriber to discuss which GLP-1 is right for your goals →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

For most Australian lifters: why Tirzepatide wins

The brief is direct: for most people who train seriously, Tirzepatide is the better tool.

The reasons are specific:

Controlled deficit. 700–800 calories per day is aggressive enough to drive meaningful fat loss at a pace compatible with maintaining training volume, recovery quality, and the protein intake needed to preserve lean mass. It is not a starvation deficit. You can eat enough to train, recover, and hit 2.2–2.6 g/kg of protein while maintaining the deficit.

Better body composition. The dual GIP/GLP-1 mechanism produces a higher proportion of fat loss relative to lean mass loss compared to single GLP-1 agents. Retatrutide's thermogenic addition does not improve this ratio — it worsens it. The SURMOUNT-1 DXA substudy data shows approximately 32–33% of Tirzepatide's total weight loss comes from lean mass — a meaningful figure for any lifter invested in the muscle they've built. The expected lean mass loss proportion on Retatrutide, given its thermogenic mechanism, is likely higher still.

Lower cardiovascular load. For anyone whose training performance and recovery depend on low resting heart rate and high HRV, the absence of glucagon-driven sympathetic activation is a meaningful practical advantage.

Sustainable timeline. A Tirzepatide protocol for a lean lifter — 8–12 week cycles with planned maintenance breaks — produces body recomposition over 6–12 months without the metabolic whiplash of a 1,200-calorie daily deficit that accelerates plateau onset.

When Retatrutide is the right choice

Retatrutide wins for one specific use case: when maximum fat loss speed is the primary goal and body composition preservation is a secondary concern.

If you have a significant amount of body fat to lose — broadly defined as more than 20 kg — and you want to lose it as quickly as possible, Retatrutide's larger deficit produces faster absolute results. The lean mass trade-off matters less when the starting lean mass proportion is lower and the fat reserve is larger.

This is the clinical profile Retatrutide was designed for: metabolically unhealthy individuals with significant obesity who need rapid weight reduction. It was not designed for an 85 kg person at 16% body fat who wants to reach 12%.

The critical caveat: Retatrutide is not currently available in Australia. It is in Phase 3 clinical trials and has not received FDA approval — which precedes TGA review by 6–18 months. There is no compounding pathway for unapproved clinical trial compounds. If a clinic is offering Retatrutide in Australia right now, verify their compliance before proceeding.

The deficit narrows — what to do when the plateau arrives

Both drugs plateau. The question is what to do when they do.

For Tirzepatide users on a training protocol, the plateau management framework is:

1. Verify the deficit is real — 7 days of food tracking to confirm caloric intake hasn't drifted up as appetite suppression adapts
2. Discuss dose titration with your prescriber — moving from 5 mg to 10 mg to 15 mg/week opens additional deficit headroom
3. Run a 10–14 day diet break at maintenance — partially reverses the leptin suppression and cortisol elevation that deepen plateaus
4. Add AOD-9604 as an adjunct — AOD-9604 activates fat cell lipolysis through a completely independent mechanism. Adding it to a stable Tirzepatide dose introduces a second deficit pathway that doesn't touch the appetite axis — exactly what plateau management needs.

For Retatrutide users (when it becomes available), the plateau management options are more limited precisely because the thermogenic deficit is already near its ceiling. This is another argument for starting with Tirzepatide — the dose ladder is longer and the adjunct options are wider.

What does the right protocol actually look like in Australia right now?

Goal	Drug choice	Cycle	Key adjunct
Body recomposition — lose fat, keep muscle	Tirzepatide (off-label, compounded)	8–12 weeks on / 8 off	Ipamorelin/CJC-1295 for lean mass support
Maximum fat loss speed	Tirzepatide at 15 mg (the highest available dose)	Continuous under medical supervision	AOD-9604 for plateau management
Significant obesity (20 kg+ to lose)	Tirzepatide or semaglutide — discuss with prescriber	Continuous	Standard monitoring
Retatrutide	Not available in Australia — wait for TGA pathway	—	—

Australian access and cost

Tirzepatide is accessible in Australia via off-label compounded prescription from an AHPRA-registered telehealth practitioner. Both Thrive Rx and Compound Clinics have practitioners with experience prescribing GLP-1 agents for body composition goals, including awareness of the lean mass preservation considerations discussed here.

Cost: $180–$380 AUD/month depending on dose and clinic.

Retatrutide is not accessible in Australia. Phase 3 TRIUMPH trials are ongoing. Anticipated Australian access timeline: 2026–2027 at earliest, pending FDA approval and subsequent TGA review.

---

ProtocolHub provides educational information only. All GLP-1 therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice.

What to read next

• Tirzepatide peptide profile — full evidence summary, TGA status, and Australian dosing
• Your Mounjaro has stopped working — how to break through a plateau — the plateau management protocol
• GLP-1 drugs eat muscle: what lean lifters need to know — the broader body composition framework
• AOD-9604 peptide profile — the complementary fat loss adjunct
• Ipamorelin + CJC-1295 — lean mass support during GLP-1 protocols
• Compare Australian GLP-1 clinics